Minerva Medica 2021 June;112(3):315-7

DOI: 10.23736/S0026-4806.21.07450-4

lingua: Inglese

Neuroendocrine neoplasms: what we have learned and what the future holds in the pharmacological treatment

Giovanni VITALE ^{1, 2} ✉, Luigi BARREA ^{3, 4}, Antonio AVERSA ⁵

¹ IRCCS Istituto Auxologico Italiano, Laboratory of Geriatric and Oncologic Neuroendocrinology Research, Cusano Milanino, Milan, Italy; ² Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy; ³ Unit of Endocrinology, Department of Clinical Medicine and Surgery, Medical School of Naples, Federico II University, Naples, Italy; ⁴ Unit of Endocrinology, Department of Clinical Medicine and Surgery, Centro Italiano per la Cura e il Benessere del Paziente con Obesità (C.I.B.O), Medical School of Naples, Federico II University, Naples, Italy; ⁵ Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy

HTML PDF

inizio pagina

I TUOI DATI

I TUOI ORDINI

CESTINO ACQUISTI

COME ORDINARE

I TUOI ABBONAMENTI

I TUOI ARTICOLI

I TUOI EBOOK

COUPON

ACCESSIBILITÀ

Minerva Medica 2021 June;112(3):315-7

Neuroendocrine neoplasms: what we have learned and what the future holds in the pharmacological treatment

Publication History

Per citare questo articolo

Corresponding author e-mail

Share